Table 7. Clinical response according to LMR-week 6 for NSCLC patients.
Response | Number (N=20, %) | Low LMR-week 6 (N=13, 65%) | High LMR-week 6 (N=7, 35%) |
---|---|---|---|
CR | 1 (5.0) | 0 (0.0) | 1 (14.3) |
PR | 4 (20.0) | 1 (7.7) | 3 (42.9) |
SD | 1 (5.0) | 0 (0.0) | 1 (14.3) |
PD | 14 (70.0) | 12 (92.3) | 2 (28.6) |
NSCLC, non-small-cell lung cancer; N, number; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; LMR-week 6, lymphocyte-to-monocyte ratio 6 weeks after the start of PD-1 inhibitors.